125073-22-5

Basic information

• Product Name: (+/-)-(1α,2α,3α,5α)-3-<(2-amino-6-chloro-4-pyrimidinyl)amino>-5-(hydroxymethyl)-1,2-cyclopentanediol
• CAS NO: 125073-22-5
• Molecular Weight: 274.707
• Mol File: 125073-22-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (+/-)-(1α,2α,3α,5α)-3-<(2-amino-6-chloro-4-pyrimidinyl)amino>-5-(hydroxymethyl)-1,2-cyclopentanediol(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-(1α,2α,3α,5α)-3-<(2-amino-6-chloro-4-pyrimidinyl)amino>-5-(hydroxymethyl)-1,2-cyclopentanediol(125073-22-5)
• EPA Substance Registry System: (+/-)-(1α,2α,3α,5α)-3-<(2-amino-6-chloro-4-pyrimidinyl)amino>-5-(hydroxymethyl)-1,2-cyclopentanediol(125073-22-5)

Safety Data

• Hazardous Substances Data: 125073-22-5(Hazardous Substances Data)

Upstream product

• 56-05-3 2-Amino-4,6-dichloropyrimidine 
• 79200-57-0 (1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxylmethyl)-1-aminocyclopentan hydrochloride 

Downstream Products

• 125073-28-1 (+/-)-(1α,2α,3α,5α)-3-(5-amino-7-chloro-3H-1,2,3-triazolo<4,5-d>pyrimidin-3-yl)-5-(hydroxymethyl)-1,2-cyclopentanediol 
• 125073-29-2 (+/-)-5-amino-3,6-dihydro-3-<(1α,2α,3α,4α)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl>-7H-1,2,3-triazolo<4,5-d>pyrimidin-7-one 
• 125073-30-5 (+/-)-(1α,2α,3α,5α)-3-(5,7-diamino-3H-1,2,3-triazolo<4,5-d>pyrimidin-3-yl)-5-(hydroxymethyl)-1,2-cyclopentanediol 
• 125073-27-0 (+/-)-(1α,2α,3α,5α)-3-(2,6-diamino-9H-purin-9-yl)-5-(hydroxymethyl)-1,2-cyclopentanediol 
• 125073-25-8 (+/-)-(1α,2α,3α,5α)-3-(2-amino-6-chloro-9H-purin-9-yl)-5-(hydroxymethyl)-1,2-cyclopentanediol 

Relevant articles and documents

Novel substituted pyrimidines as HCV replication (replicase) inhibitors

Compound 1 was identified as a HCV replication inhibitor from screening/early SAR triage. Potency improvement was achieved via modulation of substituent on the 5-azo linkage. Due to potential toxicological concern, the 5-azo linkage was replaced with 5-alkenyl or 5-alkynyl moiety. Analogs containing the 5-alkynyl linkage were found to be potent inhibitors of HCV replication. Further evaluation identified compounds 53 and 63 with good overall profile, in terms of replicon potency, selectivity and in vivo characteristics. Initial target engagement studies suggest that these novel carbanucleoside-like derivatives may inhibit the HCV replication complex (replicase).